Investments, Funding & Disinvestment

The acquisition builds on an established collaboration between Roche and PathAI that began in 2021 and expanded in 2024 to include the development of AI-enabled companion diagnostic algorithms.

The agreement excludes China, Hong Kong, Macau, and Taiwan, where SiranBio will retain rights.

Catalyst Pharmaceuticals, listed on Nasdaq in 2006, has evolved into a focused rare disease company with strong commercial momentum.

Neuralink’s clinical programme has recorded notable early milestones, including reports that its first human participant successfully operated a computer and typed using neural signals alone.

The initiative will leverage the UAE–India healthcare corridor to expand access to gene therapies for high-need populations and strengthen cross-border biomedical collaboration.

Under the agreement, Madrigal will take over the development, manufacturing, and commercialisation of Arrowhead’s investigational therapy, ARO-PNPLA3.

The acquisition comes as Bayer seeks to reinforce its position in ophthalmology amid growing biosimilar competition facing Eylea, which it co-developed with Regeneron.

The investment comes as Oman accelerates the modernization of its healthcare infrastructure through public-private collaboration and increased adoption of advanced medical technologies.

The project is backed by a conditional grant of up to C$5 million (US$3.6 million) from the Ontario government through the Invest Ontario Fund.

Photon Flash radiotherapy delivers radiation more than 100 times faster than conventional radiotherapy techniques, to reduce damage to surrounding healthy tissue while effectively targeting tumors.